Literature DB >> 8019028

Recurrent renal thrombotic angiopathy after kidney transplantation in two patients with primary antiphospholipid syndrome (PAPS).

G Mondragón-Ramírez1, T Bochicchio, R García-Torres, M C Amigo, M Martínez-Lavin, P Reyes, J Herrera-Acosta.   

Abstract

Renal artery and venous thrombosis and thrombotic microangiopathy have been related to PAPS. This condition may lead to end-stage renal disease (ESRD). We present 2 patients with PAPS and ESRD who received a living unrelated kidney transplant. Despite intensive anticoagulant therapy, the disease recurred in the grafts.

Entities:  

Mesh:

Year:  1994        PMID: 8019028

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  6 in total

Review 1.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

2.  Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome.

Authors:  V Pengo; A Biasiolo; P Marson; G De Silvestro; C Agostini; U Livi
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 3.  Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

Authors:  Maria G Tektonidou
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 4.  Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis.

Authors:  M C Amigo; R García-Torres
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.686

Review 5.  [Antiphospholipid antibody syndrome].

Authors:  R Schmidt; E H Scheuermann; A Viertel; H Geiger; I Scharrer
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 6.  Renal Involvement in Antiphospholipid Syndrome.

Authors:  Alonso Turrent-Carriles; Juan Pablo Herrera-Félix; Mary-Carmen Amigo
Journal:  Front Immunol       Date:  2018-05-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.